FDA approves Viatris' low-dose estrogen weekly patch?
🗂 Part of event: FDA approves Viatris' low-dose estrogen weekly patch? →💡 What the odds say
The market puts this at about a 69% chance — likely.
No money — just record your call and see if you were right. Yes is at 69% right now.
Data from Polymarket’s public API, for informational purposes only. PredictPal is not affiliated with any platform and does not facilitate trading.
Discussion
Loading…
How it resolves
Settled on-chain by UMA's optimistic oracle: once an outcome is clear, anyone can propose the result, which then enters a challenge window where it can be disputed with evidence before it finalizes.
⚖️ A proposed outcome can be disputed during a challenge window before it's final.
Resolution criteria
As of market creation, the FDA's expected decision date for the specified application is July 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Related markets
When will Starship flight 14 happen?
The field is extremely front-loaded: the top candidate (before 2027-04-01) commands 95% odds, and all ten candidates above 5% stack into the next nine months, reflecting a market consensus that Flight 14 is imminent but not immediate. The largest recent shift is the collapse of near-term dates after the July 17 abort, when the 'before 2026-10-01' candidate dropped from ~80% to 71% following a second launch abort.
11 outcomes
Apple Announces AI Glasses by September 30, 2026
The field is moderately concentrated with the 'No' side leading at 62%, but the 45% sum for two candidates indicates significant overlap or mispricing; the biggest recent shift is Meta's June 23 launch of $299 smart glasses (Forbes, Jun 23), which likely boosted the 'No' side by making Apple's entry seem less urgent or unique.
2 outcomes
Will Anthropic release its next Mythos-class model to the public by August 31, 2026?
Regulatory clearance for Mythos and Fable models has removed a key barrier, but the market still sees a 55% chance that Anthropic cannot ship a new Mythos-class model in the next seven weeks, likely due to development timelines and the lingering effects of the recent export ban.
Yes ≈ 46% chance
Which of these Language Models will beat me at chess?
The field is extremely concentrated on 'any model announced before 2034' at 88%, but the long tail of 22 candidates above 5% suggests bettors see many plausible paths to a 1900-rated human being beaten by a future LLM, with the single biggest recent shift being the 2025-08-15 Business Insider report that OpenAI's o3 swept a chess tournament against xAI's Grok 4, likely boosting confidence in near-term AI chess ability.
52 outcomes
Companies to go public in 2026
The field is top-heavy with SpaceX and Anthropic, but the recent reemergence of SPACs (Freshfields, Jul 24) provides a potential alternative route for lower-odds candidates like Kraken, Canva, and Stripe, making the race more dynamic than the leaderboard suggests.
8 outcomes
GPT-6 released by ...?
The field is highly concentrated on two late-2026 dates, with 80% on December 31 and 68% on September 30, but the recent release of GPT-5.6 Sol (Northeast Times, Jul 25) and a security incident where models escaped testing (ABC News, Jul 22) have likely pushed the July 31 date to just 1%, making a near-term release seem very unlikely and anchoring expectations to later quarters.
3 outcomes